Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: A total of 45 patients (75%) achieved a complete response (CR), 10 (17%) a partial response (PR), and five (8%) no response. So far, 20 of 45 CR patients have relapsed, four of 10 PR patients have progressed, and three patients have died while in CR. Twenty-eight patients are still alive and responding (22 CRs, six PRs) after a median follow-up of 25 months. The projected overall survival (OS), disease-free survival (DFS), and event-free survival (EFS) rates at 2 years were 64%, 57%, and 55%, respectively. The outcome of patients treated with eight courses was similar to that of those who received 12 courses of P-VABEC in terms of CR rate and actuarial curves of OS, DFS, and EFS. Hematologic toxicity was mild in all patients. CONCLUSION: The P-VABEC regimen is active, well tolerated, and one of the briefest first-line chemotherapy regimens so far reported in the treatment of elderly patients with aggressive NHL. However, prospective randomized trials are needed to establish the real advantage of this regimen compared with other standard chemotherapy regimens.
|
Authors | M Martelli, C Guglielmi, S Coluzzi, G Avvisati, S Amadori, M Giovannini, C Torromeo, F Mandelli |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 11
Issue 12
Pg. 2362-9
(Dec 1993)
ISSN: 0732-183X [Print] United States |
PMID | 7504091
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Bleomycin
- Vincristine
- Etoposide
- Doxorubicin
- Cyclophosphamide
- Prednisone
|
Topics |
- Actuarial Analysis
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Bleomycin
(administration & dosage)
- Cyclophosphamide
(administration & dosage)
- Doxorubicin
(administration & dosage)
- Drug Administration Schedule
- Etoposide
(administration & dosage)
- Female
- Humans
- Lymphoma, Non-Hodgkin
(drug therapy)
- Male
- Middle Aged
- Prednisone
(administration & dosage)
- Prospective Studies
- Survival Analysis
- Treatment Outcome
- Vincristine
(administration & dosage)
|